Table 1. STI prevalence disaggregated by HPV screening outcome.
| STI causing organisms | Total [n/N (%)] | HPV + [n/N (%)] | HPV— [n/N (%)] | p-value |
|---|---|---|---|---|
| N | 208 | 135 | 73 | |
| MG | 2/208 (1.0) | 2/135 (1.5) | 0 | 0.4202 |
| TV | 30/208 (14.4) | 19/135 (14.1) | 11/73 (15.1) | 0.8461 |
| HD | 0 | 0 | 0 | - |
| HSV-1 | 0 | 0 | 0 | - |
| HSV-2 | 16/208 (7.7) | 15/135 (11.1) | 1/73 (1.4) | 0.005 2 |
| TP | 36/208 (17.3) | 18/135 (13.3) | 18/73 (24.7) | 0.039 1 |
| NG | 10/208 (4.8) | 9/135 (6.7) | 1/73 (1.4) | 0.1702 |
| CT-S1-CT-S2 | 17/208 (8.2) | 11/135 (8.2) | 6/73 (8.2) | 0.2251 |
| CT-S2 | 1/208 (0.5) | 1/135 (0.7) | 0 | 1.0002 |
MG—Mycoplasma genitalium; TV–Trichomonas vaginalis; HD–Haemophilus ducreyi; HSV-1—Herpes simplex virus type 1; HSV-2: herpes simplex virus type 2; TP—Treponema pallidum; NG–Neisseria gonorrhoeae; CT—Chlamydia trachomatis.
p-value of ≤0.05 was considered statistically significant
p-values derived using Pearson’s Chi-squared test1 and Fisher’s Exact test2
proportions (%) for the columns reported as n/N